The Experts below are selected from a list of 216 Experts worldwide ranked by ideXlab platform
Qirong Wang - One of the best experts on this subject based on the ideXlab platform.
-
the efficacy of venlafaxine Flunarizine and valproic acid in the prophylaxis of vestibular migraine
Frontiers in Neurology, 2017Co-Authors: Fenye Liu, Xiaolin Che, Qirong WangAbstract:Background: Different types of medications are currently used in vestibular migraine (VM) prophylaxis, although recommendations for use are generally based on expert opinion rather than on solid data from randomized trials. We evaluated the efficacy and safety of venlafaxine , Flunarizine and valproic acid in a randomized comparison trial for VM prophylaxis. Methods: Subjects were randomly allocated to one of three groups (venlafaxine group, Flunarizine group, and valproic acid group). To assess the efficacy of treatment on vertigo symptoms, the following parameters were assessed at baseline and 3 months after treatment: Dizziness Handicap Inventory (DHI) scores, number of vertiginous attacks in the previous month, and Vertigo Severity Score. Adverse events also were evaluated. Results: A decrease in DHI total scores was shown following treatment with all three medications, with no obvious differences between the groups. Treatment effects differed, however, in the DHI physical, functional, and emotional domains with only venlafaxine showing a decreased effect in all of three domains. Flunarizine and valproic acid showed an effect in only one DHI domain. Venlafaxine and Flunarizine showed decreased VSS scores (p=0 and p=0.03, respectively). Although valproic acid had no obvious effect on VSS (p=0.27), decreased vertigo attack frequency was observed in this group (p=0). Venlafaxine also had an effect on vertigo attack frequency (p=0) but Flunarizine had no obvious effect (p=0.06). No serious adverse events were reported in the three groups. Conclusions: Our data confirm the efficacy and safety of venlafaxine, Flunarizine and valproic acid in the prophylaxis of VM, venlafaxine had an advantage in terms of emotional domains. Venlafaxine and valproic acid also was shown to be preferable to Flunarizine in decreasing the number of vertiginous attacks, but valproic acid was shown to be less effective than venlafaxine and Flunarizine to decrease vertigo severity.
-
The Efficacy of Venlafaxine, Flunarizine, and Valproic Acid in the Prophylaxis of Vestibular Migraine
Frontiers Media S.A., 2017Co-Authors: Fenye Liu, Xiaolin Che, Qirong WangAbstract:BackgroundDifferent types of medications are currently used in vestibular migraine (VM) prophylaxis, although recommendations for use are generally based on expert opinion rather than on solid data from randomized trials. We evaluated the efficacy and safety of venlafaxine, Flunarizine, and valproic acid in a randomized comparison trial for VM prophylaxis.MethodsSubjects were randomly allocated to one of three groups (venlafaxine group, Flunarizine group, and valproic acid group). To assess the efficacy of treatment on vertigo symptoms, the following parameters were assessed at baseline and 3 months after treatment: Dizziness Handicap Inventory (DHI) scores, number of vertiginous attacks in the previous month, and Vertigo Severity Score (VSS). Adverse events also were evaluated.ResultsA decrease in DHI total scores was shown following treatment with all three medications, with no obvious differences between the groups. Treatment effects differed, however, in the DHI physical, functional, and emotional domains with only venlafaxine showing a decreased effect in all of three domains. Flunarizine and valproic acid showed an effect in only one DHI domain. Venlafaxine and Flunarizine showed decreased VSS scores (p = 0 and p = 0.03, respectively). Although valproic acid had no obvious effect on VSS (p = 0.27), decreased vertigo attack frequency was observed in this group (p = 0). Venlafaxine also had an effect on vertigo attack frequency (p = 0), but Flunarizine had no obvious effect (p = 0.06). No serious adverse events were reported in the three groups.ConclusionOur data confirm the efficacy and safety of venlafaxine, Flunarizine, and valproic acid in the prophylaxis of VM, venlafaxine had an advantage in terms of emotional domains. Venlafaxine and valproic acid also were shown to be preferable to Flunarizine in decreasing the number of vertiginous attacks, but valproic acid was shown to be less effective than venlafaxine and Flunarizine to decrease vertigo severity.Trial registrationChiCTR-OPC-17011266 (http://www.chictr.org.cn/)
Fenye Liu - One of the best experts on this subject based on the ideXlab platform.
-
the efficacy of venlafaxine Flunarizine and valproic acid in the prophylaxis of vestibular migraine
Frontiers in Neurology, 2017Co-Authors: Fenye Liu, Xiaolin Che, Qirong WangAbstract:Background: Different types of medications are currently used in vestibular migraine (VM) prophylaxis, although recommendations for use are generally based on expert opinion rather than on solid data from randomized trials. We evaluated the efficacy and safety of venlafaxine , Flunarizine and valproic acid in a randomized comparison trial for VM prophylaxis. Methods: Subjects were randomly allocated to one of three groups (venlafaxine group, Flunarizine group, and valproic acid group). To assess the efficacy of treatment on vertigo symptoms, the following parameters were assessed at baseline and 3 months after treatment: Dizziness Handicap Inventory (DHI) scores, number of vertiginous attacks in the previous month, and Vertigo Severity Score. Adverse events also were evaluated. Results: A decrease in DHI total scores was shown following treatment with all three medications, with no obvious differences between the groups. Treatment effects differed, however, in the DHI physical, functional, and emotional domains with only venlafaxine showing a decreased effect in all of three domains. Flunarizine and valproic acid showed an effect in only one DHI domain. Venlafaxine and Flunarizine showed decreased VSS scores (p=0 and p=0.03, respectively). Although valproic acid had no obvious effect on VSS (p=0.27), decreased vertigo attack frequency was observed in this group (p=0). Venlafaxine also had an effect on vertigo attack frequency (p=0) but Flunarizine had no obvious effect (p=0.06). No serious adverse events were reported in the three groups. Conclusions: Our data confirm the efficacy and safety of venlafaxine, Flunarizine and valproic acid in the prophylaxis of VM, venlafaxine had an advantage in terms of emotional domains. Venlafaxine and valproic acid also was shown to be preferable to Flunarizine in decreasing the number of vertiginous attacks, but valproic acid was shown to be less effective than venlafaxine and Flunarizine to decrease vertigo severity.
-
The Efficacy of Venlafaxine, Flunarizine, and Valproic Acid in the Prophylaxis of Vestibular Migraine
Frontiers Media S.A., 2017Co-Authors: Fenye Liu, Xiaolin Che, Qirong WangAbstract:BackgroundDifferent types of medications are currently used in vestibular migraine (VM) prophylaxis, although recommendations for use are generally based on expert opinion rather than on solid data from randomized trials. We evaluated the efficacy and safety of venlafaxine, Flunarizine, and valproic acid in a randomized comparison trial for VM prophylaxis.MethodsSubjects were randomly allocated to one of three groups (venlafaxine group, Flunarizine group, and valproic acid group). To assess the efficacy of treatment on vertigo symptoms, the following parameters were assessed at baseline and 3 months after treatment: Dizziness Handicap Inventory (DHI) scores, number of vertiginous attacks in the previous month, and Vertigo Severity Score (VSS). Adverse events also were evaluated.ResultsA decrease in DHI total scores was shown following treatment with all three medications, with no obvious differences between the groups. Treatment effects differed, however, in the DHI physical, functional, and emotional domains with only venlafaxine showing a decreased effect in all of three domains. Flunarizine and valproic acid showed an effect in only one DHI domain. Venlafaxine and Flunarizine showed decreased VSS scores (p = 0 and p = 0.03, respectively). Although valproic acid had no obvious effect on VSS (p = 0.27), decreased vertigo attack frequency was observed in this group (p = 0). Venlafaxine also had an effect on vertigo attack frequency (p = 0), but Flunarizine had no obvious effect (p = 0.06). No serious adverse events were reported in the three groups.ConclusionOur data confirm the efficacy and safety of venlafaxine, Flunarizine, and valproic acid in the prophylaxis of VM, venlafaxine had an advantage in terms of emotional domains. Venlafaxine and valproic acid also were shown to be preferable to Flunarizine in decreasing the number of vertiginous attacks, but valproic acid was shown to be less effective than venlafaxine and Flunarizine to decrease vertigo severity.Trial registrationChiCTR-OPC-17011266 (http://www.chictr.org.cn/)
Yannan Fang - One of the best experts on this subject based on the ideXlab platform.
-
a randomized one year clinical trial comparing the efficacy of topiramate Flunarizine and a combination of Flunarizine and topiramate in migraine prophylaxis
Pain Medicine, 2012Co-Authors: Ning Luo, Aiwu Zhang, Ying Wang, Minghui Ding, Yingting Zhu, Mark W Massing, Yannan FangAbstract:Objectives. The objective of this study was to observe the efficacy, safety, and side effects of a combination of Flunarizine plus topiramate compared with either Flunarizine and or toparamate alone for migraine prophylaxis. Methods. Out of 150 patients with migraine recruited into the study and randomly assigned to one of three conditions, 126 completed the trial in their group: Flunarizine (39), topiramate (44), and Flunarizine plus topiramate (43). Patient information was assessed at enrollment and at follow-up visits at the end of months 1–3, 6, 9, and 12. The primary measure of efficacy reduction in mean monthly migraine frequency of at least 50% as compared with baseline. Secondary efficacy parameters included reduction in mean monthly migraine days and severity of headache. Side effects were compared in the three groups by recording adverse reactions and weight changes. Results. The proportion whose monthly headache frequency decreased more than 50% was 66.7% (26/39) in the Flunarizine group, 72.7% (32/44) in the topiramate group and 76.7% (33/43) in the combination group, respectively (P = 0.593). The mean monthly days and severity of headache in the three groups also declined and was more significant in the Flunarizine plus topiramate group than in the Flunarizine group and the topiramate group (P < 0.05). In the Flunarizine group, the average weight change was 0.6 kg. Topiramate was associated with a mean weight loss was of −0.9 kg in the topiramate group and −0.2 kg in the Flunarizine plus topiramate group. Conclusion. Flunarizine, topiramate, and the combination of Flunarizine with topiramate are all effective and have good tolerability in migraine prophylaxis. Adding topiramate to Flunarizine may reduce the latter's impact on body weight.
-
A randomized, one-year clinical trial comparing the efficacy of topiramate, Flunarizine, and a combination of Flunarizine and topiramate in migraine prophylaxis.
Pain medicine (Malden Mass.), 2012Co-Authors: Ning Luo, Aiwu Zhang, Ying Wang, Minghui Ding, Yingting Zhu, Mark W Massing, Yannan FangAbstract:Objectives. The objective of this study was to observe the efficacy, safety, and side effects of a combination of Flunarizine plus topiramate compared with either Flunarizine and or toparamate alone for migraine prophylaxis. Methods. Out of 150 patients with migraine recruited into the study and randomly assigned to one of three conditions, 126 completed the trial in their group: Flunarizine (39), topiramate (44), and Flunarizine plus topiramate (43). Patient information was assessed at enrollment and at follow-up visits at the end of months 1–3, 6, 9, and 12. The primary measure of efficacy reduction in mean monthly migraine frequency of at least 50% as compared with baseline. Secondary efficacy parameters included reduction in mean monthly migraine days and severity of headache. Side effects were compared in the three groups by recording adverse reactions and weight changes. Results. The proportion whose monthly headache frequency decreased more than 50% was 66.7% (26/39) in the Flunarizine group, 72.7% (32/44) in the topiramate group and 76.7% (33/43) in the combination group, respectively (P = 0.593). The mean monthly days and severity of headache in the three groups also declined and was more significant in the Flunarizine plus topiramate group than in the Flunarizine group and the topiramate group (P
Xiaolin Che - One of the best experts on this subject based on the ideXlab platform.
-
the efficacy of venlafaxine Flunarizine and valproic acid in the prophylaxis of vestibular migraine
Frontiers in Neurology, 2017Co-Authors: Fenye Liu, Xiaolin Che, Qirong WangAbstract:Background: Different types of medications are currently used in vestibular migraine (VM) prophylaxis, although recommendations for use are generally based on expert opinion rather than on solid data from randomized trials. We evaluated the efficacy and safety of venlafaxine , Flunarizine and valproic acid in a randomized comparison trial for VM prophylaxis. Methods: Subjects were randomly allocated to one of three groups (venlafaxine group, Flunarizine group, and valproic acid group). To assess the efficacy of treatment on vertigo symptoms, the following parameters were assessed at baseline and 3 months after treatment: Dizziness Handicap Inventory (DHI) scores, number of vertiginous attacks in the previous month, and Vertigo Severity Score. Adverse events also were evaluated. Results: A decrease in DHI total scores was shown following treatment with all three medications, with no obvious differences between the groups. Treatment effects differed, however, in the DHI physical, functional, and emotional domains with only venlafaxine showing a decreased effect in all of three domains. Flunarizine and valproic acid showed an effect in only one DHI domain. Venlafaxine and Flunarizine showed decreased VSS scores (p=0 and p=0.03, respectively). Although valproic acid had no obvious effect on VSS (p=0.27), decreased vertigo attack frequency was observed in this group (p=0). Venlafaxine also had an effect on vertigo attack frequency (p=0) but Flunarizine had no obvious effect (p=0.06). No serious adverse events were reported in the three groups. Conclusions: Our data confirm the efficacy and safety of venlafaxine, Flunarizine and valproic acid in the prophylaxis of VM, venlafaxine had an advantage in terms of emotional domains. Venlafaxine and valproic acid also was shown to be preferable to Flunarizine in decreasing the number of vertiginous attacks, but valproic acid was shown to be less effective than venlafaxine and Flunarizine to decrease vertigo severity.
-
The Efficacy of Venlafaxine, Flunarizine, and Valproic Acid in the Prophylaxis of Vestibular Migraine
Frontiers Media S.A., 2017Co-Authors: Fenye Liu, Xiaolin Che, Qirong WangAbstract:BackgroundDifferent types of medications are currently used in vestibular migraine (VM) prophylaxis, although recommendations for use are generally based on expert opinion rather than on solid data from randomized trials. We evaluated the efficacy and safety of venlafaxine, Flunarizine, and valproic acid in a randomized comparison trial for VM prophylaxis.MethodsSubjects were randomly allocated to one of three groups (venlafaxine group, Flunarizine group, and valproic acid group). To assess the efficacy of treatment on vertigo symptoms, the following parameters were assessed at baseline and 3 months after treatment: Dizziness Handicap Inventory (DHI) scores, number of vertiginous attacks in the previous month, and Vertigo Severity Score (VSS). Adverse events also were evaluated.ResultsA decrease in DHI total scores was shown following treatment with all three medications, with no obvious differences between the groups. Treatment effects differed, however, in the DHI physical, functional, and emotional domains with only venlafaxine showing a decreased effect in all of three domains. Flunarizine and valproic acid showed an effect in only one DHI domain. Venlafaxine and Flunarizine showed decreased VSS scores (p = 0 and p = 0.03, respectively). Although valproic acid had no obvious effect on VSS (p = 0.27), decreased vertigo attack frequency was observed in this group (p = 0). Venlafaxine also had an effect on vertigo attack frequency (p = 0), but Flunarizine had no obvious effect (p = 0.06). No serious adverse events were reported in the three groups.ConclusionOur data confirm the efficacy and safety of venlafaxine, Flunarizine, and valproic acid in the prophylaxis of VM, venlafaxine had an advantage in terms of emotional domains. Venlafaxine and valproic acid also were shown to be preferable to Flunarizine in decreasing the number of vertiginous attacks, but valproic acid was shown to be less effective than venlafaxine and Flunarizine to decrease vertigo severity.Trial registrationChiCTR-OPC-17011266 (http://www.chictr.org.cn/)
Raekil Park - One of the best experts on this subject based on the ideXlab platform.
-
protective effect of t type calcium channel blocker Flunarizine on cisplatin induced death of auditory cells
Hearing Research, 2005Co-Authors: Channy Park, Hyungjin Kim, Jung Han Lee, Sung Yeol Park, Jai Hyung Lee, Zee Won Lee, Hyungmin Kim, Federico Kalinec, David J Lim, Raekil ParkAbstract:Changes in intracellular Ca2+ level are involved in a number of intracellular events, including triggering of apoptosis. The role of intracellular calcium mobilization in cisplatin-induced hair cell death, however, is still unknown. In this study, the effect of calcium channel blocker Flunarizine (Sibelium), which is used to prescribe for vertigo and tinnitus, on cisplatin-induced hair cell death was investigated in a cochlear organ of Corti-derived cell line, HEI-OC1, and the neonatal (P2) rat organ of Corti explant. Cisplatin induced apoptotic cell death showing nuclear fragmentation, DNA ladder, and TUNEL positive in both HEI-OC1 and primary organ of Corti explant. Flunarizine significantly inhibited the cisplatin-induced apoptosis. Unexpectedly, Flunarizine increased the intracellular calcium ([Ca2+]i) levels of HEI-OC1. However, the protective effect of Flunarizine against cisplatin was not mediated by modulation of intracellular calcium level. Treatment of cisplatin resulted in ROS generation and lipid peroxidation in HEI-OC1. Flunarizine did not attenuate ROS production but inhibited lipid peroxidation and mitochondrial permeability transition in cisplatin-treated cells. This result suggests that the protective mechanism of Flunarizine on cisplatin-induced cytotoxicity is associated with direct inhibition of lipid peroxidation and mitochondrial permeability transition.